Kidneys Home > Votrient and Pregnancy
The cancer medicine Votrient (pazopanib) is a pregnancy Category D rating, which means that it is generally not recommended for use during pregnancy. In animal studies, the drug was shown to increase the risk of miscarriage, heart and bone defects, and other problems in the offspring. However, there may be situations in which the benefits outweigh the risks, and Votrient could be prescribed to a pregnant woman.
Can Pregnant Women Take Votrient?
What Is Pregnancy Category D?The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category D is given to medicines that have been shown to present a risk to the fetus in studies of pregnant women but may still offer benefits that outweigh the risks the drug presents.
A pregnancy Category D medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the woman outweigh the possible risks to the unborn child.
Votrient has not been adequately studied in pregnant women. When given to pregnant rats, the drug caused a variety of problems in the offspring, including heart and bone defects, low body weight, and miscarriage. When given to pregnant rabbits, it caused miscarriage and low fetal body weight. These problems occurred even with low Votrient doses.
Based on the results of these animal studies and the known actions of the medication, it may cause harm to the fetus if taken during pregnancy. Therefore, Votrient is generally not recommended for use in pregnant women. There may be times, however, when the benefits of using the medicine outweigh the risks, such as in cases where no other medicine is an option.
The manufacturer of Votrient recommends that women of childbearing potential avoid becoming pregnant while taking it. If you are a woman of childbearing potential, talk to your healthcare provider about effective forms of birth control for your individual situation.